Delving into the Latest Updates on Ivermectin with Synapse

Overview

Basic Info

SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity.

Drug Type

Small molecule drug

Synonyms

mdc-STM, CD-5024, K-237

+ [13]

Target

GluCls

Action

modulators

Mechanism

Glutamate-gated chloride channel modulators

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [3]

Active Indication

RosaceaLice InfestationsScabies+ [10]

Inactive Indication

Acne VulgarisDermatitis, AtopicPediculus capitis infestation

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Zhejiang Hisun Pharmaceutical Co., Ltd.

Merck Sharp & Dohme Corp.Merck Sharp & Dohme (Australia) Pty Ltd.

+ [9]

Inactive Organization

Galderma Research & Development SNC

Galderma Holding SATeva Pharmaceuticals USA, Inc.

+ [2]

License Organization

Medicines Patent Pool Foundation

MedinCell SA

Sol-Gel Technologies Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1996),

OnchocerciasisStrongyloidiasis

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS Registry70209-81-3

Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer treatment. However, clinical data remain virtually absent. To date, only one partially reported human study has investigated ivermectin in combination with anti-PD-1 therapy in patients with metastatic triple-negative breast cancer. Among the first nine treated patients, no treatment-related serious adverse events were observed, and the study remains ongoing.
Despite this growing interest, ivermectin's off-label use carries risks. For instance, Gilene et al. described a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A49. Moreover, the potential impact of ivermectin on the gut microbiome-a key modulator of immune checkpoint inhibitor (ICI) immunotherapy success or failure efficacy-remains poorly understood. As antibiotic exposure has been linked to diminished immunotherapy outcomes, ivermectin's antibiotic properties raise legitimate concerns about possible microbiome disruption. However, variables such as ivermectin dose, the duration of exposure, and the type of immunotherapy are each variables that remain poorly studied.
Taken together, these data underscore the urgency to prospectively evaluate ivermectin's immunologic effects in patients with cancer treated ICIs. Given ivermectin's wide availability, affordability, and public interest, rigorous clinical testing is crucial to determine whether it enhances-or potentially compromises-anticancer immunity while simultaneously assessing its safety to provide guidance for clinicians and patients.
This study will investigate the safety, pharmacodynamic effects, and potential for dose-responsive immune modulation of ivermectin given concurrently with immune checkpoint inhibitor therapy in adult subjects with solid tumors.

Start Date01 Jul 2026

Sponsor / Collaborator

University of Florida

NCT06918665

/ SuspendedPhase 1IIT

HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation

This is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. The goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. The trial will involve 52 participants who will be healthy adult volunteers. The participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).

Start Date01 Jul 2026

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

100 Clinical Results associated with Ivermectin

Login to view more data

100 Translational Medicine associated with Ivermectin

Login to view more data

100 Patents (Medical) associated with Ivermectin

Login to view more data

7,875

Literatures (Medical) associated with Ivermectin

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Treatment of redness in rosacea with potassium–titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial

Article

Author: Heidemeyer, Kristine ; Junge, Alexandra ; Lehmann, Mathias ; Bossart, Simon ; Yawalkar, Nikhil ; Seyed Jafari, S. Morteza ; Cazzaniga, Simone ; Feldmeyer, Laurence

CLINICAL TRIAL REGISTER:

clinicalTrials.gov (NCT06033352).

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Chen, Xiang ; Li, Sitong ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

01 Jun 2026·VETERINARY RESEARCH COMMUNICATIONS

Evaluation of dose escalation and drug combinations of ivermectin and fipronil as strategies for improving control of resistant Rhipicephalus microplus populations

Article

Author: Torrents, Jorgelina ; Rossner, María Victoria ; Lifschitz, Adrián ; Sarli, Macarena ; Miró, María Victoria ; Nava, Santiago

113

News (Medical) associated with Ivermectin

24 Mar 2026

·allsci.com

China’s NMPA approves Xdemvy for Demodex blepharitis, triggering USD 15m milestone to Tarsus

China’s National Medical Products Administration has approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis, making it the first therapy approved in China for Demodex blepharitis that targets the root cause of the condition. The approval, obtained by Grand Pharmaceutical Group Limited, triggers a USD 15 million milestone payment to Tarsus Pharmaceuticals, which developed the drug under the designation TP-03 and holds the US FDA approval for the same indication granted in July 2023. Lotilaner remains the only approved prescription treatment for Demodex blepharitis in any regulatory jurisdiction worldwide. The NMPA approval covers the People’s Republic of China, with Grand Pharma holding exclusive rights to develop and commercialize TP-03 across the Greater China region, including Hong Kong, Macau, and Taiwan. Grand Pharma acquired these rights from LianBio through a novation agreement executed in March 2024, assuming all obligations under the original licensing deal between LianBio and Tarsus. Under the agreement, Tarsus is eligible for additional regulatory milestones, sales threshold milestones, and tiered royalties on product sales in the region, the company said. The US FDA approval in 2023 was based on data from two Phase II/III randomized, controlled trials, Saturn-1 and Saturn-2, which enrolled patients with Demodex blepharitis. In those studies, lotilaner ophthalmic solution administered as one drop in each eye twice daily for six weeks demonstrated statistically significant rates of collarette cure — complete resolution of the cylindrical dandruff formations at the lash base that are the hallmark clinical sign of Demodex infestation. Approximately 44% of treated patients achieved collarette cure compared with roughly 7% receiving vehicle, and around 60% of patients had no detectable Demodex mites following treatment. The drug also showed significant improvements in erythema cure. The most common adverse reaction was instillation site stinging or burning. Specific clinical trial data supporting the Chinese regulatory submission were not detailed in the announcement, though the approval references the same molecule and formulation evaluated in the Saturn program. Demodex blepharitis is a chronic inflammatory eyelid condition driven by infestation with Demodex folliculorum and Demodex brevis mites. The company’s announcement references more than 40 million affected individuals in the Greater China region. Before lotilaner’s arrival, management relied on off-label approaches — tea tree oil lid scrubs, topical or oral ivermectin, lid hygiene regimens, and in-office mechanical debridement — none of which carried regulatory approval for the indication or directly eradicated the mites. Lotilaner is an isoxazoline compound originally developed by Elanco as a veterinary ectoparasiticide. It acts as a non-competitive antagonist of invertebrate gamma-aminobutyric acid-gated chloride channels, a target absent in mammalian GABA receptors, causing paralysis and death of the mites. Tarsus licenses the underlying intellectual property from Elanco Tiergesundheit AG for human health applications. No other novel molecules are in late-stage clinical development specifically for Demodex blepharitis. Tarsus is separately advancing TP-04, a related compound in Phase II for ocular rosacea, and TP-05, an oral tablet in Phase II for prevention of Lyme disease. The broader ocular surface landscape has seen recent approvals for adjacent conditions — including Miebo for dry eye disease associated with meibomian gland dysfunction and Vevye for dry eye disease, both approved in 2023 for dry eye disease. The China approval extends the geographic reach of the only targeted pharmacotherapy for a condition that has historically been under-diagnosed and managed without standardized treatment protocols. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Drug ApprovalLicense out/inPhase 2Clinical Result

19 Mar 2026

·www.einpresswire.com

OpenVet Launches the World's First Veterinary AI Skills Library for OpenClaw

VetClaw by OpenVet introduces species aware, safety-first clinical workflows designed to help advance the future of veterinary AI MIAMI, FL, UNITED STATES, March 19, 2026 / EINPresswire.com / -- OpenVet this week released VetClaw , an open-source library of 51 AI skills built specifically for veterinary medicine. It is the first veterinary skills library for OpenClaw, the open-source AI agent framework that has become the fastest-growing infrastructure project in the AI ecosystem. Until today, there were zero veterinary-specific skills available on the platform despite hundreds already existing for human medicine. VetClaw covers clinical reasoning, pharmacology, species-specific medicine, literature and evidence, patient safety and veterinary database access. The library also includes reference SDK clients for the openFDA Animal and Veterinary adverse event database, a browser-based Species Safety Checker demo, and a documented case protocol for personalized veterinary cancer immunotherapy. The release comes days after one of the most widely covered stories in veterinary AI to date. Last week, Australian tech entrepreneur Paul Conyngham used AI tools to design a personalized mRNA cancer vaccine for his rescue dog Rosie, who had been diagnosed with aggressive mast cell cancer. Working with researchers at the University of New South Wales, Conyngham sequenced Rosie's tumor DNA, used AlphaFold to model protein structures, and identified neoantigens that became the basis for a custom mRNA vaccine. The tumor shrank 75%. Researchers called it the first personalized cancer vaccine ever designed for a dog. VetClaw includes a detailed skill covering the neoantigen vaccine design pipeline adapted for veterinary patients, walking through each step from tumor sequencing and canine DLA typing through neoantigen prediction and mRNA construct design. It is the most comprehensive open-source guide currently available for veterinary personalized oncology. But the library's value goes well beyond oncology. Every skill follows a species-first, safety-first design. Drug skills require species identification before returning any result. Safety skills flag known lethal cross-species variance: acetaminophen is routine in dogs but fatal in cats. Permethrin flea products safe for dogs can kill cats in the same household. Ivermectin is safe in most dogs but neurotoxic in herding breeds carrying the MDR1 mutation. Diagnostic skills adjust differential rankings based on species and breed. The library draws on established veterinary reference materials, FDA and other government databases, and published research in animal medicine. "Veterinary AI cannot be built by taking human medical AI and swapping in animal names," said Adam Sager, CEO and co-founder of OpenVet. "The biology is different. The drug safety profiles are different. The evidence base is structured differently. Before today, none of that was represented in the tools developers are actually building with. VetClaw changes that." Andrew Heller, DVM, co-founder and Chief Operations Officer of OpenVet, said: "What the Rosie case showed is that AI-assisted veterinary medicine is real and it works. What it also showed is that every step of that pipeline still requires veterinary expertise. VetClaw was designed to encode that expertise into AI systems so they support the profession rather than bypass it." OpenClaw is an open-source AI agent framework that uses modular skills to teach AI systems how to perform specific tasks. It has been adopted by major technology companies and is used by hundreds of thousands of developers. VetClaw gives any OpenClaw-compatible agent the ability to reason about veterinary medicine with species awareness, safety constraints and clinical structure that generic AI systems lack. VetClaw is one part of OpenVet's broader work. The open-source library makes veterinary AI reasoning patterns publicly available. OpenVet's full platform at openvet.ai provides the clinical-grade environment built on that foundation, with cited evidence, specialist-level decision support and species-specific safety infrastructure for practicing veterinarians. The release extends the principles established in OpenVet's Veterinary AI Safety Charter (openvet.ai/trust-and-safety), published in January 2026 as the first public framework for responsible AI design in veterinary medicine. VetClaw is available now at github.com/OpenVet-Projects/VetClaw. About OpenVet OpenVet is the AI hospital for every animal on earth. The company builds clinical intelligence infrastructure for veterinary medicine, giving veterinarians access to cited, species-aware decision support at the point of care. VetClaw is OpenVet's open-source veterinary AI skills library, freely available to researchers, developers and the veterinary profession. The full OpenVet platform is at www.openvet.ai . Media Contact press@openvet.ai Team OpenVet OpenVet.AI email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Vaccine

02 Mar 2026

·firstwordpharma.com

Biopharma bites: More ACIP members, a public path for Candid, plus Novo's manufacturing boost and Aardvark's study pause

Two more members named to CDC vaccine panelCandid goes public in reverse merger with RallyBioNovo to boost ex-US oral GLP-1 capacityAardvark hits pause on Prader-Willi studyTwo more members named to CDC vaccine panelHealth and Human Services Secretary Robert F. Kennedy Jr. has appointed two more doctors to the Centers for Disease Control and Prevention's vaccine panel. The Advisory Committee on Immunization Practices (ACIP) now includes Sean Downing, a Florida-based physician trained in internal medicine and paediatrics, and Angelina Farella, a paediatrician based in Texas.After abruptly firing all 17 members of ACIP last year, Kennedy — a long-time critic of vaccines — has been reconstituting the panel, most recently adding two new members this past January.Similar to other new ACIP members, Farella has a past of spreading vaccine misinformation. She was a member of America's Frontline Doctors, a group that promoted the use of ivermectin and hydroxychloroquine to treat COVID-19, and also falsely claimed the vaccines were not effective in preventing infection and instead had killed 45,000 people in the US.In a 2021 interview, Farella also suggested there appeared to be a gag order on what could be discussed regarding treatment of COVID-19. "We can use all kinds of things to treat this virus," she said. "But you know what? There has been an absolute blackout on what primary care physicians can do to treat and get these patients well. That's how you crush a pandemic. Not by vaccinating."ACIP is scheduled to next meet March 18-19 and will discuss COVID-19 vaccine injury recommendations.-Anna BratulicCandid goes public in reverse merger with RallyBioA year and a half after launching, Candid Therapeutics has found a pathway to go public via a reverse merger with RallyBio. As part of the deal, the biotech raised $505 million in a private financing from Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, accounts advised by T. Rowe Price Associates, venBio Partners, Viking Global Investors, Cormorant Asset Management, Foresite Capital, Soleus Capital, TCGX and Vivo Capital. The funds, expected to give the newly public company a cash runway through 2030, will help support the development of Candid's pipeline of T-cell engagers (TCEs), gained through aggressive deal-making. At its debut, the company acquired Vignette Bio, securing ex-China rights to cizutamig (formerly) CND106, a BCMA/CD3 bispecific developed by EpimAb, and also took over TRC 2004, gaining ex-China rights to CND261, a CD20/CD3 bispecific from Genor Biopharma, originally designed by Ab Studio. The capital will support Phase II studies evaluating cizutamig in myasthenia gravis and interstitial lung disease secondary to rheumatological diseases.Candid has also inked TCE agreements with Ab Studio, Nona Biosciences, EpimAb Biotherapeutics and WuXi Biologics.-Elizabeth EatonNovo to boost ex-US oral GLP-1 capacityNovo Nordisk will invest €432 million ($506 million) in its tabletting facility in Monksland, Athlone, Ireland to increase manufacturing capacity for current and future oral GLP-1 treatments. The move will allow the site to serve as a critical hub for markets outside the US, according to the company. Construction will be finalised gradually from the end of 2027 through 2028."This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland," said Kasper Bødker Mejlvang, EVP of CMC and product supply.-Matthew DennisAardvark hits pause on Prader-Willi studyAardvark Therapeutics said it voluntarily paused its Phase III HERO trial of ARD-101 in patients with Prader-Willi Syndrome (PWS) after detecting "reversible cardiac observations" at above-target doses in a separate healthy volunteer study.Oppenheimer analyst Leland Gershell noted that the doses were two times higher than what PWS patients received in the HERO study, though that didn't sway investors. Company shares were down 56% on Monday.ARD-101 is a gut-restricted small molecule that activates intestinal bitter taste receptors, stimulating enteroendocrine cells to release gut hormones such as GLP-1 and cholecystokinin (CCK), which engage gut-brain pathways to mediate appetite.The HERO study had been evaluating ARD-101 for hyperphagia, the hallmark insatiable hunger experienced by patients with PWS. Enrollment and dosing in both the pivotal trial and its open-label extension have been halted while Aardvark conducts a safety review. As a result, the company no longer anticipates announcing topline HERO data in the third quarter, adding it intends to provide further guidance next quarter. -Anna Bratulic

Phase 2VaccinePhase 3AcquisitionExecutive Change

100 Deals associated with Ivermectin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00804	Ivermectin	D11AX22 P02CF01	DB00602

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rosacea	United States	Galderma Laboratories LP	19 Dec 2014
Lice Infestations	United States	Arbor Pharmaceuticals LLC	07 Feb 2012
Scabies	Japan	MSD KK (Tokyo)	21 Aug 2006
Ascariasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Elephantiasis, Filarial	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Enterobiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Helminthiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Hookworm Infections	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Trichuriasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Onchocerciasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996
Strongyloidiasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	Bulgaria	MedinCell SA	25 Mar 2022
Dermatitis, Atopic	Phase 2	Canada	Galderma Holding SA	01 Nov 2016
Dermatitis, Atopic	Phase 2	Canada	Galderma Research & Development SNC	01 Nov 2016
Acne Vulgaris	Phase 2	Canada	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	Canada	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Holding SA	25 Apr 2016
Pediculus capitis infestation	Phase 1	United States	Taro Pharmaceuticals U.S.A., Inc.	20 Mar 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04275999 (CTgov)	Phase 2	Rosacea	30	Ivermectin (Control Group)	xgsrnqophi(phxlmuwowt) = vpxaxykvlc ldulukpzdm (zpwrwwjpxw, rgdhazeoqa - buxcukkmot) View more	-	27 Mar 2026
				digital interaction+Ivermectin (Digital Interaction Group)	cqqbcptumj = gqwzyhybqa zcopuijuff (jqittazrxa, jrezotdcly - deuqzhopbj) View more
NCT04410406 (CTgov)	Phase 3	Elephantiasis, Filarial	164	Albendazole+Ivermectin (IA (Ivermectin + Albendazole))	xpwwpltxmo = llrxzwkvwf plnzwsvaro (wyyrgffsbp, hythipmlsj - ovfvusqyqp) View more	-	29 Jan 2026
				Albendazole+Moxidectin (MoxA (Moxidectin + Albendazole))	xpwwpltxmo = jbzcofkvks plnzwsvaro (wyyrgffsbp, vzcvvetvoe - swntmggilt) View more
NCT02407782 (Pubmed \| BMJ)	Phase 3	Scabies	1,075	Oral ivermectin	ylexfypved(uqtyolroyw) = odmptlrdvu owatfkxjzb (ousgkyzbmf ) View more	Negative	06 Jan 2026
				5% permethrin cream	ylexfypved(uqtyolroyw) = xfmglwvmwg owatfkxjzb (ousgkyzbmf ) View more
NCT04966702 (BOHEMIA, Pubmed \| EClinicalMedicine)	Phase 3	Malaria	22,724	Ivermectin to all eligible humans	grehtjcryn(jfulemwryw): IRR = 1.29 (95.0% CI, 0.62 - 2.68)	Negative	01 Dec 2025
				Ivermectin to eligible humans plus injectable ivermectin to all eligible pigs and cattle
NCT04885530 (ACTIV-6, CTgov)	Phase 3	COVID-19	10,956	Ivermectin (Arm A - Ivermectin 400)	ueyzkyqlno = zfetoytvkk ijmrxrifqk (vplnyzuggw, cwddsyaias - qfctyblmzr) View more	-	17 Nov 2025
				Fluvoxamine (Arm B - Fluvoxamine)	ueyzkyqlno = vdnnuvlmrk ijmrxrifqk (vplnyzuggw, insbdxkupc - ooydcmudzr) View more
NCT06184399 (Iverped, CTgov)	Phase 2	Trichuriasis \| Hookworm Infections \| Ascariasis	260	Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole)	spbitbjajp = wckvctvtcy bronoiycbi (gnbhaowvub, ylmcxqlojr - htbairwduo) View more	-	22 Sep 2025
				Albendazole 400 mg Oral Tablet+Ivermectin 1.5 mg ODT (Arm B: Ivermectin ODT 100 µg/kg & Albendazole)	spbitbjajp = epdgmqhhob bronoiycbi (gnbhaowvub, jzpnqlhhht - zsdroslxqe) View more
NCT04966702 (BOHEMIA, Pubmed \| N Engl J Med)	Phase 3	Malaria	28,932	Ivermectin (monthly administration for 3 consecutive months)	xiybuzxztt(vavchshrna) = mocckspgft fbjbzosljo (cvakrcjvig )	Positive	24 Jul 2025
				Albendazole (active control)	xiybuzxztt(vavchshrna) = woryirzuiv fbjbzosljo (cvakrcjvig )
NCT05318469 (phase I/II study, ASCO2025)	Phase 1/2	Metastatic Triple-Negative Breast Carcinoma	9	Balstilimab 450 mg	rvsomrlzcm(ohrjcwkwvl) = ojjuzoxjeo eitwfyogio (osmpeweenz, 15.3% - 91.7) View more	Positive	30 May 2025
NCT04966702 (Pubmed \| Infect Dis Poverty)	Phase 3	Pediculus capitis infestation	-	Ivermectin MDA	fqbyntrzit(hilzaxuhdd) = 11% lvasduwxax (ruvddykwmf )	Positive	27 Mar 2025
NCT05305560 (SAIVE, CTgov)	Phase 2	COVID-19	400	Ivermectin Tablets (Active IMP)	ezrtuxentc = xxoanxzbfi adewhhifci (rjifofapuc, xaellzhljz - kbhdmsapee) View more	-	10 Dec 2024
				Matching placebo tablets (Placebo)	ezrtuxentc = ihfhagmmbg adewhhifci (rjifofapuc, sahfqofqgc - ubveckohqu) View more